Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Cash & Equivalents (2022 - 2026)

Sagimet Biosciences' Cash & Equivalents history spans 5 years, with the latest figure at $36.6 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 43.41% to $36.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $36.6 million through Mar 2026, down 43.41% year-over-year, with the annual reading at $35.0 million for FY2025, 53.82% down from the prior year.
  • Cash & Equivalents came in at $36.6 million for Q1 2026, up from $35.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $176.8 million in Q1 2024 to a low of $158000.0 in Q4 2022.
  • The 5-year median for Cash & Equivalents is $64.7 million (2025), against an average of $64.0 million.
  • Year-over-year, Cash & Equivalents skyrocketed 47456.33% in 2023 and then plummeted 63.39% in 2025.
  • Sagimet Biosciences' Cash & Equivalents stood at $158000.0 in 2022, then surged by 47456.33% to $75.1 million in 2023, then rose by 0.93% to $75.8 million in 2024, then tumbled by 53.82% to $35.0 million in 2025, then grew by 4.58% to $36.6 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Cash & Equivalents are $36.6 million (Q1 2026), $35.0 million (Q4 2025), and $32.5 million (Q3 2025).